Context: Amiodarone-induced thyrotoxicosis (AIT) type 2 is self-limiting in nature, but most physicians are reluctant to continue amiodarone. When prednisone fails to restore euthyroidism, possibly due to mixed cases of AIT type 1 and 2, perchlorate (ClO4) might be useful as ClO4 reduces the cytotoxic effect of amiodarone on thyrocytes. Objectives: To demonstrate the feasibility of continuation of amiodarone in AIT type 2, and to evaluate the usefulness of ClO4 (given alone or in combination with prednisone) in AIT type 2. Design and setting: Randomized multicenter study in 10 Dutch hospitals. Methods: Patients with AIT type 2 were randomized to receive prednisone 30 mg/d (group A, n = 12), sodium perchlorate 500 mg twice daily (group B, n = 14) or prednisone + perchlorate (group C, n = 10); all patients continued amiodarone and were also treated with methimazole 30 mg/d . Prednisone remains the preferred treatment modality of AIT type 2, as perchlorate given alone or in combination with prednisone had no better outcomes.
INTRODUCTION
Amiodarone-induced thyrotoxicosis (AIT) type 2 is caused by a destructive thyroiditis due to direct cytotoxic effects of the drug on thyrocytes 1-3. The nature of destructive thyroiditis is that of a self-limiting disease; Clinical observations support the transient character of AIT type 2, although spontaneous recovery may take several months [4] [5] [6] [7] . Nevertheless, most physicians prefer to discontinue amiodarone treatment in AIT type 2: 66% in North America, 80% in Europe, and 94% in Latin America 8, 9 . The very nature and severity of the underlying cardiac disease, however, renders discontinuation of amiodarone medication an unattractive option in many cases, and puts the patient at risk for worsening of cardiac arrhythmias. Scattered reports suggest amiodarone can be continued safely in AIT type 2 7, [10] [11] [12] , but prospective studies in this respect are lacking. The preferred treatment of AIT type 2 according to questionnaires and clinical studies is to stop amiodarone and treat with prednisone, either alone or in combination with thionamides 4, 8, 9, 13 . The rationale behind the addition of thionamides is that it is not always possible to label AIT accurately as type 2 because mixed cases of type 2 and type 1 occur 8, 9, 14 . AIT type 1 is due to iodide-induced hyperthyroidism, occurring in patients with pre-existent thyroid disease like nontoxic goiter or latent Graves' disease. These uncertainties have led to marked differences in proposed treatment algorithms. An UK-based algorithm recommends to continue amiodarone and start with prednisone plus carbimazole and to consider potassium perchlorate if after two weeks T3 levels have not decreased 15 . KClO4 is recommended in type 1 because it acutely inhibits thyroidal iodide uptake, thereby rendering the thyroid more sensitive to thionamides. An algorithm from Turkey recommends to stop amiodarone, start with KClO4 plus methimazole and to add prednisone if after one month FT4 has not normalized or decreased by > 50% 16 . Combining prednisone and KClO4 is attractive because it may take care of mixed cases of AIT which are believed to occur in 15-27% 8, 9 . However, treatment of AIT type 2 with KClO4 alone might also be considered 10 . This strategy would avoid exposure to steroids and its related side effects, whereas KClO4-induced severe side effects like aplastic anemia have not been reported in AIT patients treated with lower doses of the drug ( ≤ 1000 mg/d) and for a shorter period (≤ 6 months) than customary in the past 13, 17 . KClO4 inhibits the cytotoxic effect of amiodarone on thyrocytes in vitro, although to a lesser extent than steroids 3 . Against this background, we had two study aims: to demonstrate the feasibility of continuation of amiodarone in AIT type 2, and to evaluate the usefulness of perchlorate in AIT type 2 (given either alone, or in combination with prednisone to shorten the time to euthyroidism). To this end, we designed a randomized multicenter clinical trial in AIT type 2 patients who continued amiodarone.
PATIENTS AND METHODS

Patients and study design
Patients were recruited from 10 centers (4 university medical centers and 6 district hospitals) in The Netherlands. Inclusion criteria were AIT type 2, and continuation of amiodarone treatment as agreed upon by treating physician and patient. AIT type 2 was ascertained if all following diagnostic criteria were met: TSH < 0.4 mU/l and FT4 > 25 pmol/l, TPO-Ab < 50 kU/l and TBII < 2 U/l, poor or no visualization of thyroid gland on 99mTc-pertechnetate scintigraphy, absence of nodular goiter (more than one nodule or a nodule > 1 cm) on ultrasonography. Exclusion criteria were no informed consent, critical illness, drug or alcohol abuse, and pregnancy. Thyroid volume was measured by ultrasonography in 14 patients. Thyroid volume was calculated using the formula width x length x thickness x 0.52 for each lobe as described previously 18 . In 22 patients it was only mentioned if the thyroid was enlarged or not. Based on this information, we divided the thyroid volumes in two categories; not enlarged (<20 ml) and enlarged (20-30 ml) . The Netherlands are an iodine replete country and none of the patients had a thyroid volume > 30 ml.
Laboratory analysis
Statistical analysis
Comparison of the baseline characteristics in the three randomization arms was done with a Kruskall-Wallis test for continuous variables and a chi-squared test for independence for categorical variables. A Mann-Whitney test was used to test for differences in age, TSH en FT4 between the excluded patients and the 36 included patients. Time to TSH ≥ 0.4 mU/L in the three groups was compared by Kaplan Meier curves and the logranktest. After logtransformation of TSH and cube root transformation of FT4, differences in trends over time by treatment group for TSH and FT4 were modeled and tested via linear random effects models. Frequencies of recurrent thyrotoxicosis and need of secondary therapy were compared between the three arms with Chi-square tests. The initial FT4 concentrations in patients who became euthyroid on initial therapy and those who did not, were compared using a Mann-Whitney test. A likelihood ratio test was performed to evaluate differences between treatment groups in blood pressure, weight, creatinine, glucose, hemoglobin and leucocytes.
Statistical analyses were done using the SPSS 12.0.2 statistical package and the R statistical computing environment version 2.13.0. In all analyses, p values < 0.05 were considered significant.
RESULTS
Patient recruitment.
Nine patients did not satisfy inclusion criteria (FT4 ≤ 25 pmol/l in 5, preference to stop amiodarone in 3, and AIT type 1 in 1), and an exclusion criterion was present in five patients (no informed consent in 4, severe concomitant illness in 1). Six out of 42 randomized patients were excluded after randomization (TBII > 2 U/l in 3, discontinuation of amiodarone by miscommunication before and 3 weeks after start of study medication in 2, moved abroad in 1). Age, TSH and FT4 were not different between the 20 excluded patients and the 36 patients composing the final study population. Table 1 shows baseline characteristics of the study population; there were no significant differences between the three groups.
Efficacy of treatment.
Figure 1 depicts thyroid function during the study period for each of the three randomized groups. Table 2 shows efficacy of thyrotoxicosis treatment. The goal to reach TSH values ≥ 0.4 mU/l was reached by initial therapy in all patients of groups A and C, but required the addition of prednisone in 4 patients (29%) of group B (P = 0.03). Time to normalization of FT4 and TSH tended to be shorter in group A, but differences between groups were not significant 
Recurrent thyrotoxicosis.
Recurrent thyrotoxicosis occurred in 3 of the 36 patients (8.3%) ( Table 2 ). The patient in group A was treated again with prednisone and methimazole, and became euthyroid within 8 weeks.
Recurrence in one patient of group C -occurring 4 weeks after reaching euthyroidism upon initial therapy at 8 weeks-was treated with methimazole only; shortly thereafter agranulocytosis developed and amiodarone was discontinued. Recurrence in the other patient of group C at 1.5 yr was treated again with triple therapy, and euthyroidism was restored in 4 weeks.
Follow-up.
Follow-up was shorter than 2 years in 3 patients: one in group C (the patient who developed agranulocytosis upon methimazole and stopped amiodarone treatment) and two patients in group B. One patient had a sudden cardiac death between 1.5 and 2.0 yr. The other patient received a cardiac transplant at 21 weeks. Both patients were euthyroid and still on amiodarone when these events occurred. Amiodarone was continued in all patients until the end of follow-up (Table 2 ). Figure 1 depicts for each group the proportion of patients per category of thyroid function during follow-up. No statistically significant differences between groups were observed, although there was a tendency to reach euthyroidism faster in group A. Figure 2 shows the course of TSH and FT4 levels during follow-up. No differences between groups were observed. The occurrence of subclinical hypothyroidism was a frequent (about 40%) and rather early phenomenon, persisting during the whole follow-up in many cases. Overt 
DISCUSSION
Euthyroidism was restored in all patients: the efficacy of initial therapy was 100% in patients randomized to receive prednisone or prednisone + perchlorate, but only 71% in the perchlorate group in which prednisone had to be added to obtain normalization of TSH. In our study the time needed for normalization of FT4 and TSH was -although not significantly-longer in groups B and C than in group A. Although it is possible that perchlorate may reduce the effect of prednisone in group C, the limited group sizes in our study preclude such speculations. In the steroid treated patients of group A, median time for normalization of FT4 was 28 days and of TSH 56 days. These data are in fair agreement with an Italian study reporting median time intervals of 30 and 90 days respectively at baseline FT4 levels of 50 ± 19 pmol/l 19 . Study medication was tolerated well. Serious side effects of perchlorate (bone marrow depression and nephrotic syndrome) were not encountered. Prednisone was the most effective treatment modality of AIT type 2. However, it is intriguing to note that perchlorate was effective in 71%. This observation raises the question if the success of perchlorate must be attributed to pharmacologic actions of the drug 1,3 , or to spontaneous recovery in the natural history of AIT type 2. If one accepts the latter explanation as more likely, the next question that arises is if prednisone really alters the natural history of the disease, i.e. shortens the time to recovery. Although many physicians would be inclined to believe so, randomized studies are lacking to substantiate this view. A recent retrospective study reported that after about 6 weeks of therapy, more than 85% of patients treated with thionamides were still thyrotoxic compared to 24% of prednisone-treated patients 20 . In contrast, another uncontrolled study found no difference between patients with or without prednisone treatment in terms of the time span . The latter study did not specify AIT type, and was biased by higher baseline FT4 in the prednisone-treated patients (60 vs 37 pmol/l) 21 . Euthyroidism was restored in all patients despite continuation of amiodarone. Our study is the first prospective and controlled trial indicating that discontinuation of amiodarone in AIT type 2 is not necessary for restoration of euthyroidism. One may argue that the time to normalize FT4 and TSH is longer when amiodarone is continued. A recent retrospective study identified 8 patients with AIT type 2 assembled in the period 2003-2008 who were treated with prednisone under continuation of amiodarone. When compared to 32 matched controls with AIT type 2 treated with prednisone after discontinuation of amiodarone, median time to first normalization of thyroid hormone levels did not significantly differ between both groups (24 and 31 days respectively) 18 . Because a higher rate of recurrences in patients continuing amiodarone, the median time for stably restoring euthyroidism was much longer in this group. To establish whether or not continuation of amiodarone in prednisone-treated AIT type 2 patients really affects cure time, will require a randomized clinical trial comparing continuation of amiodarone and stopping amiodarone. Continuation of amiodarone carries a risk on recurrent thyrotoxicosis. We observed an incidence of 8.3% at 2-yr follow-up. An open Japanese study reported 6% recurrences of AIT type 2 occurring 5-8 years after the first episode 22 . In agreement with that study, our recurrences were also mild and responded quickly to therapy. As expected there was a high incidence of hypothyroidism in our study, which -albeit frequently transient in nature-persisted in many cases until the end of follow-up. One could argue that continuation of amiodarone would result in more cases of hypothyroidism. However, this appears unlikely as well as AIT type 2 patients in whom amiodarone was discontinued, developed permanent hypothyroidism in 17% within two years after successful treatment with steroids 23 . A recently proposed algorithm recommends to discontinue amiodarone if feasible 4 . Based on our study results, we would rather recommend the opposite in AIT type 2, i.e. continue amiodarone if feasible. Our study has some limitations. We did not apply colour flow Doppler sonography to discriminate AIT types because this method was not available in all centers. The number of patients in each treatment modality is rather small in our study. In view of this limited sample size the results may not be generalized to all cases of AIT type 2, and we cannot exclude the possibility that in specific circumstances, discontinuation of amiodarone might be necessary. However, in our view these limitations are well balanced by the strengths of the study, being its prospective nature, the randomization procedure, and the complete follow-up of two years.
In conclusion, perchlorate appears less useful than steroids in the treatment of AIT type 2. Prednisone remains the preferred treatment modality, and continuation of amiodarone is feasible in AIT type 2.
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